Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Glass

Showing results (11-20 of 93) with videos related to

Pageof 10
Sort By:
Haematologica|July 5, 2006
CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cellsGerald G Wulf, Anita Boehnke, Bjoern Chapuy, et al.
Tissue Engineering|September 15, 2004
Mesengenic progenitor cells derived from human placentaGerald G Wulf, Volker Viereck, Bernhard Hemmerlein, et al.
Blood|December 31, 2005
Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphomaBertram Glass, Marita Kloess, Martin Bentz, et al.
Annals of Hematology|March 2, 2011
Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescueKarin Hohloch, Carsten Oliver Sahlmann, Vijai J Lakhani, et al.
Annals of Hematology|April 15, 2025
Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6)Stephan Fuhrmann, Maike Nickelsen, Justin Hasenkamp, et al.
Bone Marrow Transplantation|November 11, 2018
Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced diseaseGerald Wulf, Justin Hasenkamp, Wolfram Jung, et al.
British Journal of Haematology|March 8, 2008
Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphomaJorg Basecke, Martina Podleschny, Annegret Becker, et al.
Cancer|December 7, 2005
Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphomaNobert Schmitz, Marita Kloess, Marcel Reiser, et al.
Archives of Dermatology|March 19, 2008
Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cellsKjell Matthias Kaune, Mario Baumgart, Stefan Gesk, et al.
The Lancet. Haematology|November 29, 2023
CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approachPeter Dreger, Paolo Corradini, John G Gribben, et al.
Pageof 10

Showing results (11-20 of 93) with videos related to

Sort By:
Pageof 10
Haematologica|July 5, 2006
CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cellsGerald G Wulf, Anita Boehnke, Bjoern Chapuy, et al.
Tissue Engineering|September 15, 2004
Mesengenic progenitor cells derived from human placentaGerald G Wulf, Volker Viereck, Bernhard Hemmerlein, et al.
Blood|December 31, 2005
Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphomaBertram Glass, Marita Kloess, Martin Bentz, et al.
Annals of Hematology|March 2, 2011
Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescueKarin Hohloch, Carsten Oliver Sahlmann, Vijai J Lakhani, et al.
Annals of Hematology|April 15, 2025
Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6)Stephan Fuhrmann, Maike Nickelsen, Justin Hasenkamp, et al.
Bone Marrow Transplantation|November 11, 2018
Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced diseaseGerald Wulf, Justin Hasenkamp, Wolfram Jung, et al.
British Journal of Haematology|March 8, 2008
Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphomaJorg Basecke, Martina Podleschny, Annegret Becker, et al.
Cancer|December 7, 2005
Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphomaNobert Schmitz, Marita Kloess, Marcel Reiser, et al.
Archives of Dermatology|March 19, 2008
Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cellsKjell Matthias Kaune, Mario Baumgart, Stefan Gesk, et al.
The Lancet. Haematology|November 29, 2023
CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approachPeter Dreger, Paolo Corradini, John G Gribben, et al.
Pageof 10